Add BrightSurf on Google Email

Shedding light on why immunotherapy sometimes fails

Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.

SourceChiba University·JournalInternational Journal of Pharmaceutics·TypeExperimental study·DateJul 24, 2025

An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study

A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...

SourceTulane University·JournalJAMA Network Open·DateJul 17, 2025

The same technology that enables targeted immunotherapy for cancer could be used to tackle Alzheimer's

A proof-of-concept study shows that chimeric antigen receptors (CARs) can distinguish between tau tangles and various forms of toxic amyloid plaques, two key contributors to Alzheimer's disease pathology. The technology has the potential to deliver therapeutic drugs directly to affected areas of the brain with reduced side effects.

SourceBuck Institute for Research on Aging·JournalJournal of Translational Medicine·TypeExperimental study·DateJun 10, 2025

Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer

Researchers at Ben-Gurion University of the Negev have made a breakthrough in harnessing patient's own T-cells to fight off cancer by creating artificial surfaces mimicking natural immune cells. These surfaces, engineered with nanostructures, strengthen and prolong activation of T-cells, leading to more effective immunotherapy.

SourceBen-Gurion University of the Negev·JournalAdvanced Materials·TypeExperimental study·DateJun 4, 2025

Sea change in cancer care requires urgent action to strengthen oncology workforce, care delivery

Rapid advances in cancer treatment have improved long-term survival rates, but current resources and models of care in Canada do not meet the changing needs of people with cancer. The authors propose solutions such as reducing unnecessary surveillance and establishing interdisciplinary specialty clinics.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeLiterature review·DateJun 2, 2025

Stratifying the immune landscape of tongue cancer

Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.

SourceInstitute of Science Tokyo·JournalCancer Immunology Immunotherapy·TypeExperimental study·DateMay 27, 2025

Unlocking T-cell plasticity in the tumor microenvironment: Insights into cancer immunotherapy and therapeutic innovations

The review highlights three key regulatory layers of T-cell plasticity: cellular signals, metabolic reprogramming, and physical and biological factors. Innovative therapeutic strategies, such as immune checkpoint therapy and adoptive cell therapy, aim to restore T-cell function and enhance antitumor immunity.

City of Hope researchers to present cancer advances that could boost survival at the American Society of Clinical Oncology (ASCO) Annual Meeting

Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...

Oxygen deprivation promotes colon cancer growth

Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.

SourceThe University of Osaka·JournalNature Communications·TypeExperimental study·DateMay 20, 2025

Study reveals financial hardship for cancer survivors due to high-cost immunotherapies, especially among blood cancer patients

A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of Cancer Survivorship·DateMay 16, 2025

Comparison of laser-guided technology and conventional manual percutaneous lung biopsy: a single-center retrospective study

This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.

SourceNational Center for Respiratory Medicine·JournalJournal of Thoracic Disease·TypeObservational study·DateMay 6, 2025

Scientists develop super strong antibodies for new cancer treatment

Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.

SourceUniversity of Southampton·JournalNature Communications·TypeExperimental study·DateMay 1, 2025

It’s not you—it’s cancer

Researchers at Cold Spring Harbor Laboratory have identified a connection between the brain and immune system responsible for cachexia-related apathy. By targeting specific neurons and immune system proteins, they hope to improve cancer patients' quality of life and tolerance for treatments.

SourceCold Spring Harbor Laboratory·JournalScience·DateApr 10, 2025

New findings on T cell exhaustion: The body prepares early for mild to severe disease

A recent study by researchers at TUM has discovered that the body produces special T cells predisposed to exhaustion even in early infection phases of moderate diseases. This finding expands our understanding of immune response mechanisms and could help control the immune system in cancer patients or weaken excessive defenses.

SourceTechnical University of Munich (TUM)·JournalNature·TypeExperimental study·DateApr 7, 2025

Your immune cells are what they eat

Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.

SourceSalk Institute·JournalScience·DateDec 12, 2024

Study details how cancer cells fend off starvation and death from chemotherapy

Researchers at NYU Langone Health discovered two ways cancer cells evade chemotherapy's effects: by slowing down pyrimidine synthesis and activating anti-apoptotic proteins. This better understanding could lead to more effective combination therapies and diagnostic tests, ultimately improving patient outcomes.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Medicine·TypeExperimental study·DateNov 26, 2024

Polymeric cloak stabilizes cytokine complex to generate tumor-targeted nanosuperagonist

A new method to construct protein complex-based therapeutics has been discovered using a polymer cloak, which stabilizes the delivery of protein complexes and enables tumor-targeted immunomodulation. The study presents an IL-15 nanosuperagonist with enhanced efficacy and specificity, promising a safer therapy for cancer treatment.

SourceInnovation Center of NanoMedicine·TypeExperimental study·DateOct 3, 2024

Low oxygen levels in tumors could enhance some of the body’s immune responses against cancer

A recent study by Dr. Esteban Ballestar's group identifies an immune cell population that is more effective in responding against cancer cells under hypoxia. Macrophages undergo changes that enhance their ability to trigger an immune response, leading to better patient outcomes in bladder and ovarian cancers.

SourceJosep Carreras Leukaemia Research Institute·JournalScience Advances·TypeExperimental study·DateSep 19, 2024

Proteins in meat, milk, and other foods suppress gut tumors

A new study published in Frontiers in Immunology reveals that certain food proteins like milk and meat can help keep gut tumors from growing by triggering the intestinal immune system. This discovery has potential clinical implications for patients with gastrointestinal conditions.

SourceRIKEN·JournalFrontiers in Immunology·DateSep 18, 2024

Five key factors predict the response of cancer patients to immunotherapy

A study by IRB Barcelona researchers has identified five independent factors that determine patients' response and survival after receiving checkpoint inhibitors, a type of immunotherapy. These findings provide a framework for current and future biomarkers of immunotherapy response and could lead to more accurate patient classification.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature Genetics·TypeComputational simulation/modeling·DateSep 12, 2024

Scientists discover how the body's killer cells attack cancer

Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.

SourceUniversity of Southampton·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 28, 2024

Light targets cells for death and triggers immune response with laser precision

Researchers develop optogenetic system to precisely target cancer cells using light, inducing inflammatory cell death and triggering immune response. The approach aims to modulate the immune suppressive environment around cancer cells, helping T cells recognize and attack the disease.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalJournal of Molecular Biology·TypeExperimental study·DateJul 1, 2024